Ergocalciferol in Chronic Kidney Disease
Completed
- Conditions
- Chronic Kidney Disease
- Registration Number
- NCT00411294
- Lead Sponsor
- Saint Louis VA Medical Center
- Brief Summary
To examine the effect of ergocalciferol treatment on 25-hydroxyvitamin D and PTH levels in patients with CKD stage 3 and 4
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patient with CKD stage 3 or 4 whose 25-hydroxyvitamin D levels are below 30 ng/ml and plasma intact PTH levels >70 pg/ml.
Exclusion Criteria
- Patients who are on any form of active vitamin treatment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link ergocalciferol to 25-hydroxyvitamin D synthesis in CKD patients?
How does ergocalciferol compare to calcitriol in managing secondary hyperparathyroidism in CKD stages 3-4?
Which biomarkers correlate with plasma intact PTH response to vitamin D supplementation in CKD?
What adverse events are associated with ergocalciferol therapy in chronic kidney disease populations?
Are there combination therapies with ergocalciferol that improve mineral metabolism in advanced CKD?
Trial Locations
- Locations (1)
Saint Louis VA Medical Center
🇺🇸Saint Louis, Missouri, United States
Saint Louis VA Medical Center🇺🇸Saint Louis, Missouri, United States